PharmiWeb

Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of investigational targeted oral peptide for treatment of plaque ...

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies.1 Icotrokinra also showed ...

Guardrails, Not Roadblocks—How C-Suite Leaders Can Foster AI Innovation

Success in AI innovation and adoption is based on a new strategic blueprint, one where innovation is correlated with four key ...

Aima Technology Wins Multiple Cross-Industry Awards, Fully Demonstrating the Industry Development 'Upgrading' Concept

Aima ranked first in the 2025 China Customer Satisfaction Index C-CSI for its industry. Notably, only a few brands saw an ...
CNX Software

Linux 6.17 release – Main changes, Arm, RISC-V, and MIPS architectures

Here are some of the highlights of the Linux 6.17 release: Specific support for single-core processors has been removed, and ...